Due to the COVID-19 pandemic, the global Oral Anticoagulants market size is estimated to be worth US$ 14530 million in 2021 and is forecast to a readjusted size of US$ 23590 million by 2028 with a CAGR of 7.1% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Oral Anticoagulants market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Oral Anticoagulants landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Direct Thrombin Inhibitors accounting for % of the Oral Anticoagulants global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Deep Vein Thrombosis (DVT) segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Oral Anticoagulants include Johnson & Johnson, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Armatheon, Aspen, AstraZeneca and Bayer, etc. In terms of revenue, the global 3 largest players have a % market share of Oral Anticoagulants in 2021.
This report focuses on Oral Anticoagulants volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Oral Anticoagulants market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Oral Anticoagulants Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors
Segment by Application
Deep Vein Thrombosis (DVT)
Pulmonary Embolism
Acute Coronary Syndrome
Hemodialysis
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Johnson & Johnson
Bristol-Myers Squibb
Boehringer Ingelheim
Sanofi
Daiichi Sankyo
Armatheon
Aspen
AstraZeneca
Bayer
Cellceutix
Cosmo Pharmaceuticals
CSL Behring
Eisai
GSK
Marathon Pharmaceuticals
Ockham Biotech
Perosphere